المؤلفون: Aman Chauhan, Alexandre Prieur, Jill Kolesar, Susanne Arnold, Léa Payen, Younes Mahi, Berengere Vire, Madison Sands, B. Mark Evers, Dominique Joubert, Lowell Anthony

المصدر: Cancers; Volume 14; Issue 4; Pages: 863

مصطلحات موضوعية: circulating progastrin, hPG 80, blood-based diagnostic biomarker, neuroendocrine neoplasms, neuroendocrine tumors, neuroendocrine carcinoma, small-cell carcinoma

الوصف: Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG80) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG80 in NENs. Plasma hPG80 was quantified from 95 stage IV NEN patients, using DxPG80 technology (ECS Progastrin, Switzerland) and compared with hPG80 concentrations in two cohorts of healthy donor controls aged 50–80 (n = 252) and 18–25 (n = 137). Median hPG80 in NENs patients was 5.54 pM compared to 1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort (p < 0.0001). Subgroup analysis revealed median hPG80 levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; n = 25) and neuroendocrine tumors (NET; n = 70) including the small-cell lung cancer (SCLC) sub-cohort (n = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG80 in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG80 as a means of monitoring disease (NCT04750954).

وصف الملف: application/pdf

العلاقة: Tumor Microenvironment; https://dx.doi.org/10.3390/cancers14040863Test

الإتاحة: https://doi.org/10.3390/cancers14040863Test

المؤلفون: Aman Chauhan, Alexandre Prieur, Jill Kolesar, Susanne Arnold, Léa Payen, Younes Mahi, Berengere Vire, Madison Sands, B. Mark Evers, Dominique Joubert, Lowell Anthony

المصدر: Cancers, Vol 14, Iss 863, p 863 (2022)

مصطلحات موضوعية: circulating progastrin, hPG 80, blood-based diagnostic biomarker, neuroendocrine neoplasms, neuroendocrine tumors, neuroendocrine carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG 80 ) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG 80 in NENs. Plasma hPG 80 was quantified from 95 stage IV NEN patients, using DxPG 80 technology (ECS Progastrin, Switzerland) and compared with hPG 80 concentrations in two cohorts of healthy donor controls aged 50–80 ( n = 252) and 18–25 ( n = 137). Median hPG 80 in NENs patients was 5.54 pM compared to 1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort ( p < 0.0001). Subgroup analysis revealed median hPG 80 levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; n = 25) and neuroendocrine tumors (NET; n = 70) including the small-cell lung cancer (SCLC) sub-cohort ( n = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG 80 in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG 80 as a means of monitoring disease (NCT04750954).

العلاقة: https://www.mdpi.com/2072-6694/14/4/863Test; https://doaj.org/toc/2072-6694Test; https://doaj.org/article/6dd6721d72fb4668b39b3e4c67adbcf9Test

الإتاحة: https://doi.org/10.3390/cancers14040863Test
https://doaj.org/article/6dd6721d72fb4668b39b3e4c67adbcf9Test

المؤلفون: Chauhan, Aman, Prieur, Alexandre, Kolesar, Jill, Arnold, Susanne, Payen, Léa, Mahi, Younes, Vire, Berengere, Sands, Madison, Evers, B. Mark, Joubert, Dominique, Anthony, Lowell

المصدر: Markey Cancer Center Faculty Publications

مصطلحات موضوعية: circulating progastrin, hPG80, blood-based diagnostic biomarker, neuroendocrine neoplasms, neuroendocrine tumors, neuroendocrine carcinoma, small-cell carcinoma, Oncology

الوصف: Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG80) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG80 in NENs. Plasma hPG80 was quantified from 95 stage IV NEN patients, using DxPG80 technology (ECS Progastrin, Switzerland) and compared with hPG80 concentrations in two cohorts of healthy donor controls aged 50–80 (n = 252) and 18–25 (n = 137). Median hPG80 in NENs patients was 5.54 pM compared to 1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort (p < 0.0001). Subgroup analysis revealed median hPG80 levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; n = 25) and neuroendocrine tumors (NET; n = 70) including the small-cell lung cancer (SCLC) sub-cohort (n = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG80 in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG80 as a means of monitoring disease (NCT04750954).

وصف الملف: application/pdf

العلاقة: All data generated or analyzed during this study are included in this published article. Individual deidentified patient data can be shared upon request and IRB approval.; https://uknowledge.uky.edu/markey_facpub/177Test; https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1176&context=markey_facpubTest

الإتاحة: https://uknowledge.uky.edu/markey_facpub/177Test
https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1176&context=markey_facpubTest

المؤلفون: Aman Chauhan, Alexandre Prieur, Jill Kolesar, Susanne Arnold, Léa Payen, Younes Mahi, Berengere Vire, Madison Sands, B. Mark Evers, Dominique Joubert, Lowell Anthony

المصدر: Cancers, Vol 14, Iss 863, p 863 (2022)

مصطلحات موضوعية: circulating progastrin, hPG 80, blood-based diagnostic biomarker, neuroendocrine neoplasms, neuroendocrine tumors, neuroendocrine carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, envir, socio

الوصف: Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG 80 ) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG 80 in NENs. Plasma hPG 80 was quantified from 95 stage IV NEN patients, using DxPG 80 technology (ECS Progastrin, Switzerland) and compared with hPG 80 concentrations in two cohorts of healthy donor controls aged 50–80 ( n = 252) and 18–25 ( n = 137). Median hPG 80 in NENs patients was 5.54 pM compared to 1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort ( p < 0.0001). Subgroup analysis revealed median hPG 80 levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; n = 25) and neuroendocrine tumors (NET; n = 70) including the small-cell lung cancer (SCLC) sub-cohort ( n = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG 80 in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG 80 as a means of monitoring disease (NCT04750954).

العلاقة: https://doi.org/10.3390/cancers14040863Test

الإتاحة: https://doi.org/10.3390/cancers14040863Test